Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465950 | 0.82 | PLAU (0.51) | PLAUHCAR2MCL1LMNAL3MBTL1 | |
| SCHEMBL4976345 | 0.79 | ALDH1A1 (0.45) | HCAR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL287761 | 0.79 | LMNA (0.47) | PLAUHCAR2LMNAL3MBTL1MEN1 | |
| SCHEMBL31006673 | 0.78 | PTPN1 (0.49) | PLAULMNAL3MBTL1PTPN1MEN1 | |
| SCHEMBL22610076 | 0.78 | ALDH1A1 (0.40) | PLAUPTPN1EGLN1ALDH1A1KDM4E | |
| SCHEMBL16634805 | 0.78 | PTPN1 (0.49) | PLAULMNAL3MBTL1PTPN1MEN1 | |
| SCHEMBL23413510 | 0.78 | LMNA (0.46) | PLAUHCAR2LMNAL3MBTL1MEN1 | |
| SCHEMBL8514986 | 0.78 | SPR (0.48) | HCAR2LMNAL3MBTL1EGLN1MEN1 | |
| SCHEMBL9684853 | 0.78 | ALDH1A1 (0.45) | HCAR2LMNAL3MBTL1SORT1MEN1 | |
| Hydrochloric Acid SCHEMBL20139726 | 0.78 | LMNA (0.46) | PLAUHCAR2LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734979-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | GILEAD SCIENCES, INC. | 2026-01-22 | — | — | US | disclosed |
| US-12441754-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-4615573-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4594316-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250026748-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | REPARE THERAPEUTICS INC. (CA) | 2025-01-23 | — | — | US | disclosed |
| WO-2025006723-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111699193-A | Novel galactoside galectin inhibitors | 格莱克特生物技术公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | JONES BENJAMIN (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3676251-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019060850-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-28 | — | — | WO | disclosed |
| US-10239863-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180179180-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20160257668-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3054944-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054087-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | POLK, POLQ, POLB | PLAU 3386/4885HCAR2 3345/4885MCL1 593/4885 |
| US-20250026748-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | POLA1, POLL, POLD1 | PLAU 3757/4885HCAR2 2709/4885MCL1 347/4885 |
| US-20180179180-A1 | Factor XIa Inhibitors | F11, SERPINC1, TFPI | PLAU 25/4885HCAR2 1833/4885MCL1 3962/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PLAU 3585/4885HCAR2 3818/4885MCL1 939/4885 |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | P4HA1, HRH3, HRH1 | PLAU 4469/4885HCAR2 134/4885MCL1 2251/4885 |
| US-20160257668-A1 | Factor XIa Inhibitors | F11, SERPINC1, TFPI | PLAU 25/4885HCAR2 1833/4885MCL1 3962/4885 |
| US-12441754-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | PLAU 721/4885HCAR2 3547/4885MCL1 812/4885 |
| US-10239863-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | PLAU 25/4885HCAR2 1833/4885MCL1 3962/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | PLAU 2539/4885HCAR2 722/4885MCL1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.